Compound reference
Retatrutide
Also referenced as: LY3437943
Retatrutide (LY3437943) reference material: receptor-class chemistry, published clinical-trial research areas, purity/identity testing, and cold-chain storage specifications.
Identity and class
Triple hormone receptor agonist peptide (GIP/GLP-1/glucagon receptor)
A synthetic, fatty-acid-conjugated peptide engineered as a single-molecule agonist at three distinct incretin/glucagon receptor targets.
A large, lipidated peptide with a molecular weight in the multi-kilodalton range, consistent with other long-acting incretin-class analogs.
Published research areas
The subject matter of published laboratory literature. Listed as what was studied — not as an effect, and not as a use in humans.
- Published clinical trial data have examined retatrutide's receptor-binding activity at GIP, GLP-1, and glucagon receptor targets.
- Peer-reviewed trial publications have examined retatrutide dosing regimens in controlled human clinical trial populations (data reported in the primary literature, not applicable to laboratory reference material).
Handling and storage
- Supplied as a lyophilized powder.
- Manufacturer-recommended storage: -20°C, protected from light; cold-chain shipping recommended.
Citations
- Triple hormone receptor agonist retatrutide
New England Journal of Medicine · 2023